MedPath

Atovaquone

ATOVAQUONE Oral Suspension These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION. ATOVAQUONE Oral Suspension Initial U.S. Approval: 1992

Approved
Approval ID

de0e29b5-a4c7-405c-a5b9-438729d9ba3a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 21, 2023

Manufacturers
FDA

Chartwell RX, LLC

DUNS: 079394054

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Atovaquone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62135-528
Application NumberANDA207833
Product Classification
M
Marketing Category
C73584
G
Generic Name
Atovaquone
Product Specifications
Route of AdministrationORAL
Effective DateJuly 21, 2023
FDA Product Classification

INGREDIENTS (6)

POLOXAMER 188Inactive
Code: LQA7B6G8JG
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
BENZYL ALCOHOLInactive
Code: LKG8494WBH
Classification: IACT
SACCHARIN SODIUMInactive
Code: SB8ZUX40TY
Classification: IACT
ATOVAQUONEActive
Quantity: 750 mg in 5 mL
Code: Y883P1Z2LT
Classification: ACTIB
XANTHAN GUMInactive
Code: TTV12P4NEE
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Atovaquone - FDA Drug Approval Details